Contact
searchSearch
HMP Global
Login

News

News
FDA Approves Dostarlimab-gxly for dMMR Advanced Solid Tumors
08/18/2021
The FDA granted accelerated approval dostarlimab-gxly. for the treatment of adult patients with mismatch repair, deficient recurrent, or advanced solid tumors
The FDA granted accelerated approval dostarlimab-gxly. for the treatment of adult patients with mismatch repair, deficient recurrent, or advanced solid tumors
The FDA granted accelerated...
08/18/2021
Oncology
News
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
06/17/2021
The FDA approved avapritinib for the treatment of adults with advanced systemic mastocytosis (SM), including those with aggressive SM, SM with an associated hematologic neoplasm, and mast cell leukemia.
The FDA approved avapritinib for the treatment of adults with advanced systemic mastocytosis (SM), including those with aggressive SM, SM with an associated hematologic neoplasm, and mast cell leukemia.
The FDA approved avapritinib for...
06/17/2021
Oncology
News
Reducing Depression in Post-Treatment Cancer Survivors
03/11/2021
There may be more effective treatment options when it comes to managing depression symptoms among cancer survivors, according to Jane McKusker, MD, DrPH, et al.
There may be more effective treatment options when it comes to managing depression symptoms among cancer survivors, according to Jane McKusker, MD, DrPH, et al.
There may be more effective...
03/11/2021
Oncology
News
Daratumumab–CyBorD Combo Tolerable, Effective in Newly Diagnosed AL Amyloidosis
02/28/2021
In a study of patients with light chain (AL) amyloidosis, daratumumab plus CyBorD was shown to produce robust responses and was well-tolerated.
In a study of patients with light chain (AL) amyloidosis, daratumumab plus CyBorD was shown to produce robust responses and was well-tolerated.
In a study of patients with...
02/28/2021
Oncology
News
FDA Approves Daratumumab–Hyaluronidase Plus VCd for AL Amyloidosis
01/26/2021
The FDA has approved daratumumab plus hyaluronidase combined with bortezomib, cyclophosphamide, and dexamethasone (VCd) for patients with newly-diagnosed AL amyloidosis.
The FDA has approved daratumumab plus hyaluronidase combined with bortezomib, cyclophosphamide, and dexamethasone (VCd) for patients with newly-diagnosed AL amyloidosis.
The FDA has approved daratumumab...
01/26/2021
Oncology
News
Risk Factors for Adverse COVID-19 Outcomes in Patients With Cancer
12/29/2020
Study data show that although cytotoxic chemo is not tied to adverse COVID-19 outcomes, hematologic and lung malignancies, lymphopenia, and neutropenia are.
Study data show that although cytotoxic chemo is not tied to adverse COVID-19 outcomes, hematologic and lung malignancies, lymphopenia, and neutropenia are.
Study data show that although...
12/29/2020
Oncology
News
Postsurgery HSRT Safer Than Whole-Brain RT for Brain Metastases
12/28/2020
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
In a study on the outcomes of...
12/28/2020
Oncology
News
Coffee May Reduce Risk for Disease Progression, Death in Patients With CRC
11/12/2020
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
Findings from a cohort study of...
11/12/2020
Oncology
News
Adult Cancer Survivors Need Better Posttreatment Care, Survey Finds
11/09/2020
Survey responses from adult cancer survivors underscore the need for improved survivorship care models that involve integrated care and a smoother transition from therapy.
Survey responses from adult cancer survivors underscore the need for improved survivorship care models that involve integrated care and a smoother transition from therapy.
Survey responses from adult...
11/09/2020
Oncology
News
FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumors
10/26/2020
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
The FDA has approved the NGS...
10/26/2020
Oncology

Recent News

News
Zongertinib Demonstrates Clinical Promise in HER2-Mutated Non-Small Cell Lung Cancer
05/14/2026
Stephanie Holland
First-line treatment with zongertinib showed sustained efficacy in advanced or metastatic HER2-mutated non-small-cell lung cancer, according to results from the phase 1a/1b Beamion LUNG-1 trial.
First-line treatment with zongertinib showed sustained efficacy in advanced or metastatic HER2-mutated non-small-cell lung cancer, according to results from the phase 1a/1b Beamion LUNG-1 trial.
First-line treatment with...
05/14/2026
Oncology
FDA Alerts
FDA Issues Safety Alert on Tazemetostat Following Secondary Malignancy Risk
05/13/2026
Emily Estrada
The FDA issued a safety alert regarding tazemetostat, citing an increased risk of hematologic second primary malignancies observed in the ongoing SYMPHONY-1 trial.
The FDA issued a safety alert regarding tazemetostat, citing an increased risk of hematologic second primary malignancies observed in the ongoing SYMPHONY-1 trial.
The FDA issued a safety alert...
05/13/2026
Oncology
FDA Approval
FDA Approves Sonrotoclax for Patients With Relapsed/Refractory Mantle Cell Lymphoma
05/13/2026
Emily Estrada
Based on results from the BGB-11417-201 trial, the FDA has approved sonrotoclax for previously treated patients with relapsed/refractory mantle cell lymphoma.
Based on results from the BGB-11417-201 trial, the FDA has approved sonrotoclax for previously treated patients with relapsed/refractory mantle cell lymphoma.
Based on results from the...
05/13/2026
Oncology
FDA Approval
FDA Approves Oral Decitabine and Cedazuridine Plus Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
05/13/2026
Janelle Bradley
The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
The FDA granted approval to the...
05/13/2026
Oncology
News
Tucatinib Plus T-DM1 Shows Sustained Disease Control in HER2-Positive Advanced Breast Cancer
05/13/2026
Emily Estrada
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Final results from the phase 3...
05/13/2026
Oncology
News
Trastuzumab Deruxtecan Plus Paclitaxel, Trastuzumab, and Pertuzumab Improves Residual Cancer Burden in HER2-Positive Early Breast Cancer
05/11/2026
Stephanie Holland
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
Post hoc analysis results from...
05/11/2026
Oncology
News
Sacituzumab Govitecan Plus Trastuzumab Showed Limited Activity After T-DXd in HER2-Positive Metastatic Breast Cancer
05/11/2026
Stephanie Holland
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
According to results from the...
05/11/2026
Oncology
FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology
News
Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma
05/07/2026
Stephanie Holland
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
05/07/2026
Oncology
FDA Approval
FDA Approves Extended-Release Ruxolitinib Across Hematologic Indications
05/07/2026
Stephanie Holland
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic...
05/07/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use